Total Raised

$283.2M

Investors Count

16

Deal Terms

3

Funding, Valuation & Revenue

12 Fundings

GenapSys has raised $283.2M over 12 rounds.

GenapSys's latest funding round was a Asset Sale for on September 8, 2022.

GenapSys's latest post-money valuation is from September 2022.

Sign up for a free demo to see GenapSys's valuations in September 2022 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

9/8/2022

Asset Sale

$XXM

0

FY undefined

2

5/27/2021

Series D - II

$41.5M

$XXM

0

FY undefined

1

3/4/2021

Series D

$28.5M

Nazem & Company, Prologis Ventures, and Undisclosed Investors

$XXM

0

FY undefined

2

4/10/2020

Loan

$XXM

$XXM

0

FY undefined

0

2/6/2020

Series C - II

$XXM

$XXM

0

FY undefined

10

Date

9/8/2022

5/27/2021

3/4/2021

4/10/2020

2/6/2020

Round

Asset Sale

Series D - II

Series D

Loan

Series C - II

Amount

$41.5M

$28.5M

$XXM

$XXM

Investors

Nazem & Company, Prologis Ventures, and Undisclosed Investors

Valuation

$XXM

$XXM

$XXM

$XXM

$XXM

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

2

1

2

0

10

Start free trial
New call-to-action

GenapSys Deal Terms

3 Deal Terms

GenapSys's deal structure is available for 3 funding rounds, including their Asset Sale from September 08, 2022.

Round

Asset Sale

Series B

Series A

Funding Date

$XXM

$XXM

$XXM

Pre-Money Valuation

Post-Money Valuation

$XXM

Amount Raised

$XXM

$XXM

Shares Authorized

Issuance Price

$XXM

Dividend Rate

$XXM

Liquidation Preferences

$XXM

Liquidation Price

Participation

Conversion Price

Anti Dilution

$XXM

General Voting

$XXM

$XXM

$XXM

Board Voting

$XXM

$XXM

$XXM

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Asset Sale

$XXM

$XXM

$XXM

$XXM

Series B

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

Series A

$XXM

$XXM

$XXM

$XXM

GenapSys Investors

16 Investors

GenapSys has 16 investors. Sequence Health invested in GenapSys's Asset Sale funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

9/8/2022

9/8/2022

1
Asset Sale

Academic/University

Georgia

5/27/2021

5/27/2021

1
Series D - II

Asset/Investment Management

California

5/27/2021

5/27/2021

1
Series D - II

Private Equity

Connecticut

00/00/0000

00/00/0000

Prologis Ventures

Subscribe to see more

Corporate Venture

California

00/00/0000

00/00/0000

Nazem & Company

Subscribe to see more

Hedge Fund

New York

First funding

9/8/2022

5/27/2021

5/27/2021

00/00/0000

00/00/0000

Last Funding

9/8/2022

5/27/2021

5/27/2021

00/00/0000

00/00/0000

Investor

Prologis Ventures

Nazem & Company

Rounds

1
Asset Sale
1
Series D - II
1
Series D - II

Subscribe to see more

Subscribe to see more

Board Seats

Type

Academic/University

Asset/Investment Management

Private Equity

Corporate Venture

Hedge Fund

Location

Georgia

California

Connecticut

California

New York

New call-to-action

Compare GenapSys to Competitors

PerkinElmer Logo
PerkinElmer

PerkinElmer operates as a provider of technology and service solutions in the laboratory sector, focusing on food, industrial, life sciences, and environmental markets. The company offers a range of products and services, including laboratory technologies for analysis and characterization, atomic spectroscopy, chromatography, and food quality analyzers. PerkinElmer's solutions help customers evaluate the quality and safety of products. It was founded in 1937 and is based in Shelton, Connecticut.

A
Algorithmic Biologics

Algorithmic Biologics provides molecular computing solutions for diagnostics and research in the life sciences industry. The company offers cloud-delivered services that improve the processes of PCR, NGS, mass spectrometry, assay design, and drug discovery. Algorithmic Biologics serves sectors that require molecular analysis and diagnostics, including healthcare and pharmaceutical research. It was founded in 2021 and is based in Bengaluru, India.

American Biosystems Logo
American Biosystems

American Biosystems produces enzymes and direct-fed microbials for sectors within the agriculture and wastewater treatment industries. Their product offerings include fermentation products and enzyme blends aimed at animal nutrition, aquaculture systems, and municipal and industrial wastewater treatment processes. The company serves the aquaculture industry, wastewater treatment facilities, and the agricultural sector with animal feed additives. It is based in Roanoke, Virginia.

Cellectis Logo
Cellectis

Cellectis is a clinical-stage biotechnology company specializing in gene editing within the biopharmaceutical sector, focusing on developing treatments for cancer through its TALEN technology. The company offers a gene editing platform that enables the creation of allogeneic CAR-T cells, with a primary focus on immuno-oncology and gene therapy. Cellectis is involved in the process of gene and cell therapy, from manufacturing to product development, and collaborates with various companies to advance treatments in oncology, immunology, and rare diseases. It was founded in 1999 and is based in Paris, France.

PTC Therapeutics Logo
PTC Therapeutics

PTC Therapeutics is a biopharmaceutical company involved in the research and development of medicines for children and adults with diseases that have significant unmet medical needs. The company develops therapies for rare diseases, including splicing modifiers and treatments for conditions like Duchenne muscular dystrophy and Friedreich's ataxia. PTC Therapeutics serves the healthcare sector, providing treatment options and assistance for patients and healthcare providers. It was founded in 1998 and is based in South Plainfield, New Jersey.

Sartorius Logo
Sartorius

Sartorius focuses in life sciences research and biopharmaceutical manufacturing, providing laboratory instruments and consumables. The company supplies solutions for drug discovery, development, and production platforms for biomanufacturing, with an emphasis on single-use products for bioprocessing. Sartorius serves pharmaceutical and biopharmaceutical companies, as well as academic research institutions. It was founded in 1870 and is based in Goettingen, Germany.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.